Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security
Holders.

Eagle Pharmaceuticals,Inc., or the Company, held its 2017 annual
meeting of stockholders, or the Annual Meeting, on June20, 2017,
at which a quorum was present. At the Annual Meeting, the
stockholders of the Company voted on the below proposals, each of
which is described in more detail in the Companys definitive
proxy statement on Schedule 14A, or the 2017 Proxy Statement,
filed with the U.S. Securities and Exchange Commission on
April28, 2017. The following sets forth the certified voting
results, including the number of votes cast for and against each
matter, and if applicable, the number of abstentions and broker
non-votes with respect to each matter.

(i) The stockholders elected two directors to serve as members of
the Companys board of directors until the 2020 annual meeting of
stockholders. The stockholders present in person or by proxy cast
the following numbers of votes in connection with the election of
directors, resulting in the election of all director nominees:

(ii) The stockholders ratified the selection by the audit
committee of the Companys board of directors of BDO USA, LLP as
the independent registered public accounting firm of the Company
for fiscal year 2017.There were 14,149,433 votes cast for the
proposal; 47,119 votes cast against the proposal; 36,615
abstentions; and there were no broker non-votes.

(iii) The stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers, as
disclosed in the 2017 Proxy Statement. There were 8,355,389 votes
cast for the proposal; 4,886,133 votes cast against the proposal;
38,825 abstentions; and there were 952,820 broker non-votes.

About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas.

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information

Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session up +0.47 at 33.08 with 5,603,626 shares trading hands.